Table 3.

Analysis of prognostic factors for survival

	N	Median survival (month; 95% CI)	p values
Gender			0.13
Male	59	11.0 (7.6–14.4)
Female	11	8.0 (1.5–14.5)
Age, y			0.033
<50	22	17.0 (17.0–17.0)
≥ 50	48	8.0 (6.3–9.7)
AFP, ng/L			0.438
≤ 20	14	8.0 (2.9–13.1)
21–399	18	14.0 (11.9–16.1)
≥ 400	38	8.0 (5.6–10.4)
Additional treatment after RT			0.00
SBRT alone	20	3.0 (1.1–4.9)
SBRT+TACE	46	12.0 (8.9–15.1)
Radiation Dose			0.376
≤ 27.5Gy	4	3.0 (0–8.9)
30-35Gy	25	8.0 (6.8–9.2)
≥ 40Gy	41	11.0 (7.7–14.3)
Origination of PVTT			0.079
Right branch	49	8.0 (5.8–10.2)
Left branch	21	13.0 (8.5–17.5)
Type of tumor thrombosis			0.107
Type II	42	8.0 (5.5–10.5)
Type III	27	14.0 (8.6–19.4)
Response (3 m after SBRT)			0.000
CR	6	*
PR	43	13.0 (10.0–16.0)
SD	4	**
PD	9	4.0 (1.1–6.9)

Abbreviations: SBRT Stereotactic body radiotherapy, AFP Alpha-fetoprotein, RT Radiotherapy, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease. * The medium survival for patients with CR was not reported because only two patients died in 7th and 11th month. The other four patients were alive, 1 patient with 15 months follow-up, 3 patients with 16 months follow-up after SBRT. ** In the four patients with SD, 3 patients died in the 8th, 8th and 11th month, the other patient was alive with 12 months follow-up